1
Clinical Trials associated with CT101A-19An open-label, single-center and single-arm clinical study of infusion of anti-CD19 or CD22 CAR-T cells (CT101A-19 or CT102A-22) for patients with relapsed/refractory/high risk B cell malignancies.
Start Date17 Jun 2019 |
Sponsor / Collaborator- |
100 Clinical Results associated with CT101A-19
100 Translational Medicine associated with CT101A-19
100 Patents (Medical) associated with CT101A-19
100 Deals associated with CT101A-19